## ANZGOG Publications – 2005 to 2016

### 2016


### 2015


---

N/A

---
for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO), Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO), National Cancer Research Institute (NCRI), Australia New Zealand Gynaecological Oncology Group (ANZOGOG), and the Mario Negri Gynecologic Oncology group (MaNGO). Epidermal Growth Factor Receptor (EGFR) pathway biomarkers in the randomized phase III trial of erlotinib versus observation in ovarian cancer patients with no evidence of disease progression after first-line platinum-based chemotherapy. Target Oncol. 2015 May 26. [Epub ahead of print]


2014


2013


5. Michael Friedlander and Madeleine King. Patient reported outcomes in ovarian cancer clinical trials. *Annals of Oncology* (accepted for publication)


2012


2011


ICON7


N/A


PARAGON

2010


5. Quinn M. Progress in ovarian cancer trials: the GCIG consensus model--is bigger, better? Gynecol Oncol. 2010 Oct;119(1):5-6. N/A


2009


<table>
<thead>
<tr>
<th>Year</th>
<th>Reference</th>
</tr>
</thead>
</table>